KDM1A and prostate carcinoma: In line with the above observation, LSD1 inhibitors (LSD1i) including IMG-7289, CC-90011, and SP2577 are currently undergoing clinical study for treatment of cancers, such as AML, SCLC, prostate cancer, and Ewing sarcoma28,29.